640 related articles for article (PubMed ID: 10729360)
1. Inhibition of the P-glycoprotein- and multidrug resistance protein-mediated efflux of anthracyclines and calceinacetoxymethyl ester by PAK-104P.
Marbeuf-Gueye C; Salerno M; Quidu P; Garnier-Suillerot A
Eur J Pharmacol; 2000 Mar; 391(3):207-16. PubMed ID: 10729360
[TBL] [Abstract][Full Text] [Related]
2. Reversal of multidrug resistance-associated protein-mediated drug resistance by the pyridine analog PAK-104P.
Sumizawa T; Chen ZS; Chuman Y; Seto K; Furukawa T; Haraguchi M; Tani A; Shudo N; Akiyama SI
Mol Pharmacol; 1997 Mar; 51(3):399-405. PubMed ID: 9058594
[TBL] [Abstract][Full Text] [Related]
3. ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P.
Chen ZS; Furukawa T; Sumizawa T; Ono K; Ueda K; Seto K; Akiyama SI
Mol Pharmacol; 1999 May; 55(5):921-8. PubMed ID: 10220571
[TBL] [Abstract][Full Text] [Related]
4. Reversal of MRP-mediated vincristine resistance in KB cells by buthionine sulfoximine in combination with PAK-104P.
Chuman Y; Chen ZS; Seto K; Sumizawa T; Furukawa T; Tani A; Haraguchi M; Niwa K; Yamada K; Aikou T; Akiyama S
Cancer Lett; 1998 Jul; 129(1):69-76. PubMed ID: 9714337
[TBL] [Abstract][Full Text] [Related]
5. PAK-104P, a pyridine analogue, reverses paclitaxel and doxorubicin resistance in cell lines and nude mice bearing xenografts that overexpress the multidrug resistance protein.
Vanhoefer U; Cao S; Minderman H; Tóth K; Scheper RJ; Slovak ML; Rustum YM
Clin Cancer Res; 1996 Feb; 2(2):369-77. PubMed ID: 9816180
[TBL] [Abstract][Full Text] [Related]
6. Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter.
Chen ZS; Kawabe T; Ono M; Aoki S; Sumizawa T; Furukawa T; Uchiumi T; Wada M; Kuwano M; Akiyama SI
Mol Pharmacol; 1999 Dec; 56(6):1219-28. PubMed ID: 10570049
[TBL] [Abstract][Full Text] [Related]
7. ATP-dependent efflux of calcein by the multidrug resistance protein (MRP): no inhibition by intracellular glutathione depletion.
Feller N; Broxterman HJ; Währer DC; Pinedo HM
FEBS Lett; 1995 Jul; 368(2):385-8. PubMed ID: 7628644
[TBL] [Abstract][Full Text] [Related]
8. Kinetic analysis of calcein and calcein-acetoxymethylester efflux mediated by the multidrug resistance protein and P-glycoprotein.
Essodaigui M; Broxterman HJ; Garnier-Suillerot A
Biochemistry; 1998 Feb; 37(8):2243-50. PubMed ID: 9485370
[TBL] [Abstract][Full Text] [Related]
9. Two pyridine analogues with more effective ability to reverse multidrug resistance and with lower calcium channel blocking activity than their dihydropyridine counterparts.
Shudo N; Mizoguchi T; Kiyosue T; Arita M; Yoshimura A; Seto K; Sakoda R; Akiyama S
Cancer Res; 1990 May; 50(10):3055-61. PubMed ID: 1970752
[TBL] [Abstract][Full Text] [Related]
10. Energy-dependent efflux from Leishmania promastigotes of substrates of the mammalian multidrug resistance pumps.
Essodaïgui M; Frézard F; Moreira ES; Dagger F; Garnier-Suillerot A
Mol Biochem Parasitol; 1999 May; 100(1):73-84. PubMed ID: 10376995
[TBL] [Abstract][Full Text] [Related]
11. Kinetics of anthracycline efflux from multidrug resistance protein-expressing cancer cells compared with P-glycoprotein-expressing cancer cells.
Marbeuf-Gueye C; Broxterman HJ; Dubru F; Priebe W; Garnier-Suillerot A
Mol Pharmacol; 1998 Jan; 53(1):141-7. PubMed ID: 9443942
[TBL] [Abstract][Full Text] [Related]
12. Reversal of LRP-associated drug resistance in colon carcinoma SW-620 cells.
Kitazono M; Okumura H; Ikeda R; Sumizawa T; Furukawa T; Nagayama S; Seto K; Aikou T; Akiyama S
Int J Cancer; 2001 Jan; 91(1):126-31. PubMed ID: 11149411
[TBL] [Abstract][Full Text] [Related]
13. Relation between the ability of some compounds to modulate the MRP1-mediated efflux of glutathione and to inhibit the MRPl-mediated efflux of daunorubicin.
Salerno M; Loechariyakul P; Saengkhae C; Garnier-Suillerot A
Biochem Pharmacol; 2004 Dec; 68(11):2159-65. PubMed ID: 15498506
[TBL] [Abstract][Full Text] [Related]
14. Reversal of heavy metal resistance in multidrug-resistant human KB carcinoma cells.
Chen ZS; Mutoh M; Sumizawa T; Furukawa T; Haraguchi M; Tani A; Akiyama S
Biochem Biophys Res Commun; 1997 Jul; 236(3):586-90. PubMed ID: 9245693
[TBL] [Abstract][Full Text] [Related]
15. MRP1 modulation by PAK-104P: detection with technetium-99m-MIBI in cultured lung tumor cells.
Vergote J; Moretti JL; Kouyoumdjian JC; Garnier-Suillerot A
Anticancer Res; 2002; 22(1A):251-6. PubMed ID: 12017298
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the kinetics of active efflux of 99mTc-MIBI in cells with P-glycoprotein-mediated and multidrug-resistance protein-associated multidrug-resistance phenotypes.
Vergote J; Moretti JL; de Vries EG; Garnier-Suillerot A
Eur J Biochem; 1998 Feb; 252(1):140-6. PubMed ID: 9523723
[TBL] [Abstract][Full Text] [Related]
17. Kinetic analysis in living cells of the inhibition of the P-glycoprotein-mediated efflux of anthracyclines by vinca alkaloids.
Pereira E; Tarasiuk J; Garnier-Suillerot A
Chem Biol Interact; 1998 Jul; 114(1-2):61-76. PubMed ID: 9744556
[TBL] [Abstract][Full Text] [Related]
18. Use of the anionic dye carboxy-2',7'-dichlorofluorescein for sensitive flow cytometric detection of multidrug resistance-associated protein activity.
Laupeze B; Amiot L; Courtois A; Vernhet L; Drenou B; Fauchet R; Fardel O
Int J Oncol; 1999 Sep; 15(3):571-6. PubMed ID: 10427142
[TBL] [Abstract][Full Text] [Related]
19. DiOC2(3) is not a substrate for multidrug resistance protein (MRP)-mediated drug efflux.
Minderman H; Vanhoefer U; Toth K; Yin MB; Minderman MD; Wrzosek C; Slovak ML; Rustum YM
Cytometry; 1996 Sep; 25(1):14-20. PubMed ID: 8875050
[TBL] [Abstract][Full Text] [Related]
20. Multidrug resistance-associated protein: a protein distinct from P-glycoprotein involved in cytotoxic drug expulsion.
Barrand MA; Bagrij T; Neo SY
Gen Pharmacol; 1997 May; 28(5):639-45. PubMed ID: 9184795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
